INSYS Therapeutics, Inc.
http://www.insysrx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From INSYS Therapeutics, Inc.
Galapagos Expands Point-Of-Care CAR-T Study To The US
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
Podcast: Thermo Fisher’s Meron Mathias On Why Environmental Sustainability Must Be A Top Priority
Meron Mathias is vice president of CSR and sustainability at Thermo Fisher, whose specialty diagnostics division makes it the fifth leading player by revenues in the global IVD industry. In this podcast, she reflects on Thermo Fisher’s early commitment to ESG and sustainability reporting, its Scope 1, 2 and 3 targets and how regulation is moving industry towards a mandatory disclosure landscape.
Flagship Inks Another Big Pharma Development Deal, This Time With GSK
The deal includes up to 10 medicines, with an initial focus on immunology and respiratory diseases, and is similar to one the VC firm made with Pfizer last year.
China’s Public Payer Challenged To Support Domestic Innovative Drug Market
One Chinese biotech executive is entertaining hopes of China’s domestic market for novel drugs growing to CNY300bn ($41bn). However, the country’s public payer spent just CNY90bn on such products in 2023 and is expected to increase expenditure to more than CNY100bn this year.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Other Names / Subsidiaries
-
- NeoPharm, Inc.
- Fresenius Biotech GmbH
- Neovii Biotech GmbH
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice